Free Trial
NASDAQ:NEXI

NexImmune (NEXI) Stock Price, News & Analysis

NexImmune logo

About NexImmune Stock (NASDAQ:NEXI)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
$0.00
$0.10
52-Week Range
N/A
Volume
N/A
Average Volume
6,478 shs
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Receive NEXI Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for NexImmune and its competitors with MarketBeat's FREE daily newsletter.

NEXI Stock News Headlines

NexImmune moves forward with wind-down process
This Signal Only Flashes Once Every 4 Years – And It Just Triggered
This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in crypto. Now it’s back, and the smart money is already positioning. A free training reveals the step-by-step strategy and altcoin picks designed to help you capitalize on the next wave.
NEXI Stock Alert: NexImmune Delists From Nasdaq
What Is Going on With NexImmune (NEXI) Stock Today?
See More Headlines

NEXI Stock Analysis - Frequently Asked Questions

NexImmune, Inc. (NASDAQ:NEXI) posted its quarterly earnings results on Friday, November, 12th. The company reported ($16.25) earnings per share for the quarter, topping the consensus estimate of ($16.75) by $0.50.

Shares of NexImmune reverse split on the morning of Thursday, October 19th 2023.The 1-25 reverse split was announced on Wednesday, October 18th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, October 18th 2023. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split.

NexImmune (NEXI) raised $75 million in an initial public offering on Friday, February 12th 2021. The company issued 4,700,000 shares at $15.00-$17.00 per share. Barclays, Cantor, Raymond James and Allen & Co. served as the underwriters for the IPO.

Shares of NEXI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that NexImmune investors own include Athenex (ATNX), Achilles Therapeutics (ACHL), TherapeuticsMD (TXMD), Bolt Biotherapeutics (BOLT), KLX Energy Services (KLXE), Lannett (LCI) and Exela Technologies (XELA).

Company Calendar

Last Earnings
11/12/2021
Today
7/12/2025
Next Earnings (Estimated)
8/05/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:NEXI
CIK
1538210
Fax
N/A
Employees
6
Year Founded
N/A

Profitability

EPS (Trailing Twelve Months)
($18.54)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$32.34 million
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
-534.32%
Return on Assets
-213.72%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.66
Quick Ratio
0.66

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.32 per share
Price / Book
N/A

Miscellaneous

Outstanding Shares
1,395,000
Free Float
1,187,000
Market Cap
N/A
Optionable
Not Optionable
Beta
1.94
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:NEXI) was last updated on 7/12/2025 by MarketBeat.com Staff
From Our Partners